Seroatlas · Human Serome Atlas

LYSMD3

LysM and putative peptidoglycan-binding domain-containing protein 3

Also known as: FLJ13542, LYSM3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q7Z3D4
Gene: LYSMD3
Ensembl: ENSG00000176018
Chromosome: 5
Canonical length: 306 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Cytosol

OverviewNCBI Gene

Enables peptidoglycan binding activity. Involved in Golgi organization. Located in Golgi membrane and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

306 residues, UniProt reviewed canonical sequence.

>Q7Z3D4|LYSMD3
     1  MAGRHQNRSF PLPGVQSSGQ VHAFGNCSDS DILEEDAEVY ELRSRGKEKV RRSTSRDRLD
    61  DIIVLTKDIQ EGDTLNAIAL QYCCTVADIK RVNNLISDQD FFALRSIKIP VKKFSSLTET
   121  LCPPKGRQTS RHSSVQYSSE QQEILPANDS LAYSDSAGSF LKEVDRDIEQ IVKCTDNKRE
   181  NLNEVVSALT AQQMRFEPDN KNTQRKDPYY GADWGIGWWT AVVIMLIVGI ITPVFYLLYY
   241  EILAKVDVSH HSTVDSSHLH SKITPPSQQR EMENGIVPTK GIHFSQQDDH KLYSQDSQSP
   301  AAQQET

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYSMD3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.59
Highest tissue expression: 23 nTPM

Expression across tissuesHPA

Tissue

liver: 23 nTPM
parathyroid gland: 17 nTPM
thyroid gland: 17 nTPM
placenta: 16 nTPM
tongue: 15 nTPM
adrenal gland: 14 nTPM

Single-cell type

neutrophils: 88 nCPM
plasma cells: 77 nCPM
tuft cells: 58 nCPM
mast cells: 55 nCPM
somatotrophs: 54 nCPM
esophageal apical cells: 53 nCPM

Immune cell

basophil: 54 nTPM
NK-cell: 19 nTPM
eosinophil: 18 nTPM
neutrophil: 17 nTPM
non-classical monocyte: 15 nTPM
MAIT T-cell: 15 nTPM

Brain region

choroid plexus: 24 nTPM
cerebellum: 17 nTPM
white matter: 13 nTPM
midbrain: 13 nTPM
hypothalamus: 12 nTPM
cerebral cortex: 11 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.62
gnomAD pLI: 0.3
gnomAD missense Z: 0.32
DepMap mean gene effect: 0.14
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Golgi organization

Molecular functions

peptidoglycan binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYSMD3 as an antibody target. Whether an autoantibody or antibody against LYSMD3 could matter depends on whether native LYSMD3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYSMD3 is annotated at the cell surface, where native LYSMD3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LYSMD3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...